Navigation Links
Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
Date:5/21/2013

ly plus pegylated interferon and ribavirin for 12 weeks, followed by pegylated interferon and ribavirin alone for either 12 or 36 weeks based on response-guided therapy criteria. Patients in the simeprevir arm were considered to have met response-guided therapy criteria if their HCV RNA levels were <25 IU/mL (detectable or undetectable) at week 4 and <25 IU/mL undetectable at week 12. In patients meeting response-guided therapy criteria, HCV therapy was stopped at week 24. All other patients continued treatment until week 48.

About Simeprevir
Simeprevir (TMC435) is an investigational NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease, including all stages of liver fibrosis. Simeprevir works by blocking the protease enzyme that enables the hepatitis C virus to replicate in host cells. New drug applications were recently submitted for simeprevir in Japan and the United States for the treatment of genotype 1 hepatitis C, and a Marketing Authorisation Application was submitted to the European Medicines Agency seeking approval of simeprevir for the treatment of genotype 1 or genotype 4 chronic hepatitis C. The U.S. FDA has granted Priority Review to the New Drug Application.

Global Phase 3 studies of simeprevir include PROMISE in adult patients who have relapsed after prior interferon-based treatment, QUEST-1 and QUEST-2 in treatment-naïve adult patients, and ATTAIN in prior null-responder adult patients. In parallel to these trials, Phase 3 studies for simeprevir are ongoing in treatment-naïve and treatment-experienced HIV-HCV co-infected patients and HCV genotype 4 patients. To date, 3,787 patients have been treated with simeprevir in clinical trials.

Simeprevir is also being studied in Phase 2 interferon-free trials with and without riba
'/>"/>

SOURCE Janssen R&D Ireland
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. PharmacyGPO Buying Group Selects H. D. Smith as Primary National Distributor
2. Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival
3. Healthscope to commercially launch Circadians Cancers of Unknown Primary Diagnostic Test
4. Medical Oncology Association of Southern California Purchasing Network (MPN) Names Cardinal Health Specialty Solutions as its Primary Healthcare Solutions Partner
5. Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study
6. Jeffrey Modell Foundation Opens Diagnostic Center for Primary Immunodeficiencies at Midwest Immunology Clinic
7. MultiCell Technologies Updates Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer in vitro Models
8. GeneTex, Inc. to Launch a New Primary Antibody against HIF1a
9. Albireo Has Been Granted Orphan Drug Designation for A4250 from the US FDA for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) and for Primary Biliary Cirrhosis (PBC)
10. AcelRx Announces Achievement of the Primary End-Point in Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System and Plans to Hold a Conference Call and Webcast Tomorrow to Discuss Top-Line Results
11. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)...  Northwest Biotherapeutics (NASDAQ: NWBO ) (NW ... for solid tumor cancers, announced today that the $17.5 ... 2014, has closed.  The three-year notes have a 5% ... of common stock.  The investors also have an option, ... additional 30% of these notes on the same terms. ...
(Date:8/19/2014)... Aug. 19, 2014  Tokyo-based Atonarp Inc. announced ... round led by Walden Riverwood Ventures with participation ... of Atonarp,s Smart Spectrometer technology platform, which will ... has targeted the oil & gas and healthcare ... are excited to partner with Atonarp in pursuing ...
(Date:8/19/2014)... 19, 2014 Avizia, Inc., a leading provider ... closed an equity financing round led by NextGen Angels ... new funding will be used to continue to fuel ... Avizia welcomes Edward Kennedy , CEO and president ... joins Leonard Kurtzman , CFO of newBrandAnalytics, who ...
Breaking Medicine Technology:NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 2NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 3Atonarp Inc. Raises $8M Series A Round Led by Walden Riverwood Ventures 2Avizia Closes Funding Round 2
(Date:8/20/2014)... “Have you recently been involved in an auto accident?” asks ... the greater Seattle area. “Are you still feeling the physical ... . , In a recently released article, Dax Jones asks ... use to see if they may qualify for a personal ... will allow an individual to receive medical treatment for their ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 The ... (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin ... Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast ... major drivers,restraints, challenges, opportunities, current market trends,and strategies ... the estimates and forecasts of the revenue and ...
(Date:8/20/2014)... 20, 2014 Mixberry Media announced today ... websites and create a new source of revenue. , ... by listening to a narration of their favorite news ... and languages. Users can now multitask: read/write email, ... while consuming content. , Mixberry Media’s service ...
(Date:8/20/2014)... Astoria, New York (PRWEB) August 20, 2014 ... to the Global Bureau of Disease, low back pain is ... of the most common reasons for missed work. Americans spend ... of this pain. , Most cases of back pain are ... a mechanical (non-organic) origin. , For example, Pete, a busy ...
(Date:8/19/2014)... 20, 2014 Midtown Dentistry in Houston, Texas, ... office. All patients with cavities, or with old fillings ... fillings that can safely repair and restore teeth. , From ... latest materials, all of which are completely amalgam free. Even ... use by the FDA for adults and children over the ...
Breaking Medicine News(10 mins):Health News:Five Questions to Determine Who Qualifies for a Personal Injury Claim Recently Released by The Jones Firm in Recent Article 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Mixberry Media, First To Offer Article Voice Narration with Integrated Audio Advertising 2Health News:Physical Therapists Learn to Relieve Low Back Pain 2Health News:Midtown Dentistry Announces It Is Now an Amalgam-Free Office 2
... , , WASHINGTON , Jan. 13 ... and Bruce A. Mrusek , a resident of Maineville, Ohio , ... Judge Michael R. Barrett in Cincinnati , the Justice Department ... both dentists, wer e i n d ...
... say , WEDNESDAY, Jan. 13 (HealthDay News) -- ... tendon doesn,t appear to be effective, a new study ... plasma (PRP) injections are no better than placebo in ... active. , The study included 54 patients, aged 18 ...
... And rates among boys aged 6-19 still climbing, government study ... news in the war on weight: Obesity in the United ... studies show. , But the rates of obesity remain high, ... category. And, rates of obesity among already heavy 6- to ...
... researchers have found that six essential oils from thyme, ... COX-2 enzyme, in a manner similar to resveratrol, the ... They also identified that the chemical carvacrol was primarily ... appearing in the January issue of Journal of ...
... ... to provide fully integrated topical clinical phase 1 study services for trials in healthy ... , ... January 13, 2010 -- Synomics Pharma and BioScience Laboratories, Inc. announced a formal partnership ...
... January 21st ... Understand the Latest Developments in VoIP Fax Capabilities, , ... Tigard, Oregon (Vocus) January 13, 2010 -- FaxBack , the ... the Miami Beach Convention Center. , , , , ,At the show, FaxBack (booth ...
Cached Medicine News:Health News:Two Cincinnati Dentists Plead Guilty to Conspiracy, Tax Evasion on Eve of Trial 2Health News: U.S. Obesity Rates Leveling Off, But Still High 2Health News: U.S. Obesity Rates Leveling Off, But Still High 3Health News:Synomics Pharma and Bioscience Laboratories Announce Partnership to Provide Topical Clinical Phase 1 Study Services 2Health News:Synomics Pharma and Bioscience Laboratories Announce Partnership to Provide Topical Clinical Phase 1 Study Services 3Health News:FaxBack Participates in VoIP Fax Discussion at ITEXPO 2Health News:FaxBack Participates in VoIP Fax Discussion at ITEXPO 3
Inquire...
... brings you into the new age of ... offer your patients immediate, long-term results for ... This injectable filler offers superior versatility for ... reconstructive treatments. Long-lasting, Radiesse saves time and ...
... HEMOCHRON Response is a whole ... to be used at the ... easy-to-read screen and data management ... ID options. QC and operator ...
... Revitol Cellulite Cream is a revolutionary ... eliminating inches. Revitol Cellulite Removal Cream permits ... problem areas. With Revitol you can rid ... Just apply the Cellulite Cream to your ...
Medicine Products: